| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5399 | 2010 |
| Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ... New England Journal of Medicine 377 (9), 829-838, 2017 | 2330 | 2017 |
| Crizotinib in ROS1-rearranged non–small-cell lung cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 2149 | 2014 |
| ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ... Journal of clinical oncology 30 (8), 863-870, 2012 | 1957 | 2012 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1542 | 2012 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1271 | 2018 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1138 | 2011 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1041 | 2019 |
| The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ... Cancer discovery 10 (1), 54-71, 2020 | 999 | 2020 |
| Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 … JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ... The lancet oncology 16 (7), 830-838, 2015 | 991 | 2015 |
| Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs SH Ou, F Wu, D Harrich, LF García-Martínez, RB Gaynor Journal of virology 69 (6), 3584-3596, 1995 | 934 | 1995 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 785 | 2017 |
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG … SM Gadgeel, L Gandhi, GJ Riely, AA Chiappori, HL West, MC Azada, ... The Lancet Oncology 15 (10), 1119-1128, 2014 | 783 | 2014 |
| Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study BJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, ... The Lancet Oncology 19 (12), 1654-1667, 2018 | 759 | 2018 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015 | 741 | 2015 |
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study SHI Ou, JS Ahn, L De Petris, R Govindan, JCH Yang, B Hughes, H Lena, ... Journal of clinical oncology 34 (7), 661-668, 2016 | 715 | 2016 |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar, H West, DR Camidge, ... The lancet oncology 17 (2), 234-242, 2016 | 707 | 2016 |
| Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ... Journal of Clinical Oncology 33 (17), 1881, 2015 | 684 | 2015 |
| ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013 | 637 | 2013 |
| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 601 | 2021 |
